← Back to Clinical Trials
Recruiting NCT06782789
NCT06782789 An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT06782789 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Diffuse Large B Cell Lymphoma (DLBCL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 96 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-08 |
Trial Parameters
Condition Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Type OBSERVATIONAL
Phase N/A
Enrollment 96
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-01
Completion 2026-08
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study is pilot, observational, retrospective, Italian multicenter study.
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed diagnosis of R/R DLBCL. 2. Patientswho received at least one dose of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017), between April 2022 and December 2022. 3. Age ≥ 18 years at enrollment. 4. Signature of written informed consent (if applicable). Exclusion Criteria: 1\) R/R DLBCL patients who received tafasitamab in association with lenalidomide in a clinical trial context.
Related Trials
NCT06782789
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the
View Trial →
NCT07493109
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With
View Trial →
NCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma P
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology